Rovi: 2018 results preview: Revenues growth of +9% but –7% EBITDA on higher R&D
Rovi: 2018 results preview: Revenues growth of +9% but –7% EBITDA on higher R&D
- Rovi will announce its 2018 results on Tuesday, 26th February before the opening. There will be a conference call that morning.
- Sales driven by Hibor and Other pharma
- Margins recover, R&D eats into the margin
- Two licenses recently acquired
- New target price
Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Bankinter S.A. is a Spanish brokerage firm established in 1989. The company's line of business includes the provision of market research and trading services for Equity and Fixed Income products.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.